公开(公告)号：EP3725805A1

公开(公告)日：2020-10-21

申请号：EP20157418.3

申请日：2013-09-05

申请人： Novartis AG

发明人： BARDROFF, Michael Otto ,  BRANNETTI, Barbara ,  CAMPBELL, Emma Michelle ,  DIEFENBACH-STREIBER, Beate ,  EBERTH, Adina ,  KUNZ, Christian Carsten Silvester ,  MARSHALL, Sylwia ,  RONDEAU, Jean-Michel Rene ,  SCHLAEPPI, Jean-Marc Alfred ,  VAN HEEKE, Gino Anselmus

IPC分类号： C07K16/24 ,  A61K39/395 ,  G01N33/50

摘要： IL-18 participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.

公开(公告)号：EP2892923B1

公开(公告)日：2020-03-25

申请号：EP13792452.8

申请日：2013-09-05

申请人： Novartis AG

发明人： BARDROFF, Michael Otto ,  BRANNETTI, Barbara ,  CAMPBELL, Emma Michelle ,  DIEFENBACH-STREIBER, Beate ,  EBERTH, Adina ,  KUNZ, Christian Carsten Silvester ,  MARSHALL, Sylwia ,  RONDEAU, Jean-Michel Rene ,  SCHLAEPPI, Jean-Marc Alfred ,  VAN HEEKE, Gino Anselmus

IPC分类号： C07K16/24 ,  A61K39/395 ,  G01N33/50

公开(公告)号：EP3347377A1

公开(公告)日：2018-07-18

申请号：EP16766396.2

申请日：2016-09-07

申请人： Novartis AG

发明人： RONDEAU, Jean-Michel Rene ,  EDWARDS, Matthew John ,  MILLER, Danforth ,  HUANG, Daniel ,  HEMMIG, Rene ,  KNOPF, Hans-Peter ,  GUPTA, Kapil ,  VAN HEEKE, Gino Anselmus ,  HAUBST, Nicole ,  ANDLAUER, Barbara

IPC分类号： C07K16/24 ,  A61K9/00 ,  A61P11/06 ,  A61P37/08

CPC分类号： C07K16/24 ,  A61K9/0043 ,  A61K9/0075 ,  A61K9/1617 ,  A61K9/1623 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/544 ,  A61K2039/545 ,  A61P11/06 ,  A61P37/08 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.

公开(公告)号：EP2847221B1

公开(公告)日：2018-06-20

申请号：EP13742049.3

申请日：2013-05-08

申请人： Novartis AG

发明人： BROWN, Zarin ,  BRADLEY, Michelle ,  CHARLTON, Steven John ,  VAN HEEKE, Gino Anselmus ,  CROMIE, Karen ,  DOMBRECHT, Bruno ,  STEFFENSEN, Soren ,  BAUMEISTER, Judith ,  BOUCHE, Marie-Paule ,  BOUTTON, Carlo ,  BUYSE, Marie-Ange ,  SNOECK, Veerle ,  STAELENS, Stephanie

IPC分类号： C07K16/28

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K16/468 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31

摘要： The present invention relates to polypeptides directed against or specifically binding to CXC chemokine receptor 2 (“CXCR2”) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

公开(公告)号：EP2892923A2

公开(公告)日：2015-07-15

申请号：EP13792452.8

申请日：2013-09-05

申请人： Novartis AG

发明人： BARDROFF, Michael Otto ,  BRANNETTI, Barbara ,  CAMPBELL, Emma Michelle ,  DIEFENBACH-STREIBER, Beate ,  EBERTH, Adina ,  KUNZ, Christian Carsten Silvester ,  MARSHALL, Sylwia ,  RONDEAU, Jean-Michel Rene ,  SCHLAEPPI, Jean-Marc Alfred ,  VAN HEEKE, Gino Anselmus

IPC分类号： C07K16/24 ,  A61K39/395 ,  G01N33/50

摘要： Interleukin 18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.

摘要翻译： 白介素18（IL-18）参与了先天免疫和获得性免疫。 IL-18的生物活性受到IL-18结合蛋白（IL18BP）（天然存在和高度特异性抑制剂）的负调控。 该可溶性蛋白质与游离IL-18形成复合物，防止其与IL-18受体的相互作用，从而中和并抑制其生物学活性。 本发明公开了结合IL-18并且不结合IL-18BP（IL-18 / IL-18BP复合物）的IL-18的结合分子，特别是抗体或其片段。 除了其生理作用，IL-18已被证明可以介导各种自身免疫性和炎性疾病。 本发明的结合分子可用作治疗IL-18相关的自身免疫性和炎症性疾病的治疗分子，或作为用于表征，检测和/或测定IL-18BP未结合的IL-18作为总IL的组分的诊断工具 -18游泳池。

公开(公告)号：EP2847221A2

公开(公告)日：2015-03-18

申请号：EP13742049.3

申请日：2013-05-08

申请人： Novartis AG

发明人： BROWN, Zarin ,  BRADLEY, Michelle ,  CHARLTON, Steven John ,  VAN HEEKE, Gino Anselmus ,  CROMIE, Karen ,  DOMBRECHT, Bruno ,  STEFFENSEN, Soren ,  BAUMEISTER, Judith ,  BOUCHE, Marie-Paule ,  BOUTTON, Carlo ,  BUYSE, Marie-Ange ,  SNOECK, Veerle ,  STAELENS, Stephanie

IPC分类号： C07K16/28

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K16/468 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31

摘要： The present invention relates to polypeptides directed against or specifically binding to CXC chemokine receptor 2 (“CXCR2”) and in particular to polypeptides capable of modulating signal transduction from CXCR2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of CXCR2.

摘要翻译： 本发明涉及针对或特异性结合趋化因子受体CXCR2的多肽，特别涉及能够调节CXCR2的信号转导的多肽。 本发明还涉及能够表达本发明多肽的核酸，载体和宿主细胞，包含所述多肽的药物组合物以及所述多肽和组合物用于治疗涉及CXCR2异常功能的疾病的用途。